Protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1), also known as MYT1. Due to its overexpression in various malignant tumors such as ovarian cancer, breast cancer, renal cancer, prostate cancer, and bladder cancer, it is a highly promising target for cancer therapy.
ReadCrystal has completed the protein expression and structural analysis of the PKMYT1 target. Based on these experimental conditions and the available protein stock, we have shortened the project delivery time to 1-2 months and ensured the successful completion of the project.
PKMYT1 Protein
Protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1), also known as MYT1, is a member of the WEE family of kinases. It negatively regulates mitosis in non-malignant eukaryotic somatic cells and plays an important role in controlling the cell cycle and maintaining normal DNA replication.
PKMYT1 specifically promotes the phosphorylation of CDK1 in the cyclin-dependent kinase complex, which is involved in cell cycle regulation. This phosphorylation causes the CDK1-cyclin B complex to remain in the cytoplasm, reducing its translocation to the nucleus and thereby disrupting the distribution of the cell cycle.
Numerous studies have shown that PKMYT1 is highly expressed in various malignant tumors, including ovarian cancer, breast cancer, renal cancer, prostate cancer, and bladder cancer. It acts as an oncogene in the progression of these cancers.
Our Capability
PKMYT1 protein experimental results
Protein Purification Result(Period: In Stock/3 weeks)
Figure 1 PKMYT1 Protein Purification Result
Crystallization and Structural Analysis(Period: 1-2 weeks)